Generic Ortho Tri-Cyclen Lo Availability
See also: Generic Ortho Tri-Cyclen
ORTHO TRI-CYCLEN LO (ethinyl estradiol; norgestimate - tablet;oral-28)
Manufacturer: JANSSEN PHARMS
Approval date: August 22, 2002
Strength(s): 0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG [RLD] [AB]
Has a generic version of Ortho Tri-Cyclen Lo been approved?
A generic version of Ortho Tri-Cyclen Lo has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Ortho Tri-Cyclen Lo and have been approved by the FDA:
Manufacturer: LUPIN PHARMS
Approval date: June 25, 2012
Strength(s): 0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG [AB]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ortho Tri-Cyclen Lo. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Triphasic oral contraceptive
Issued: April 10, 2001
Inventor(s): Shangold; Gary & Rubin; Arkady & Upmalis; David
Assignee(s): Ortho-McNeil Pharmaceuticals, Inc.
A method of contraception in which an estrogen and a progestogen are administered daily in a three phase sequence for 21 days is disclosed. In the first phase a combination of an estrogen and a progestogen in a low but contraceptively effective daily dosage corresponding in estrogenic activity to 23-28 .mu.g of 17.alpha.-ethinylestradiol and in progestogenic activity to 0.065-0.75 mg of norethindrone is administered for 5-8 days; followed by the administering of the same dosage of estrogen and a progestogen corresponding in progestogenic activity to 0.25-1.0 mg of norethindrone for 7-11 days; followed by the administering of the same dosage of estrogen and a progestogen corresponding in progestogenic activity to 0.35-2.0 mg of norethindrone for 3-7 days; followed by 4-8 days without administering either an estrogen or a progestogen.Patent expiration dates:
- June 9, 2019✓
- December 9, 2019✓
- June 9, 2019
- Ortho Tri-Cyclen Lo Consumer Information (Cerner Multum)
- Ortho Tri-Cyclen Lo Advanced Consumer Information (Micromedex®)
- Ortho-Tri-Cyclen Consumer Information (Wolters Kluwer)
- Norgestimate and ethinyl estradiol Consumer Information (Wolters Kluwer)
- 3ethinyl estradiol and norgestimate Consumer Information (Cerner Multum)
- Ethinyl estradiol and norgestimate Consumer Information (Cerner Multum)
- TriNessa 28 Advanced Consumer Information (Micromedex®)
- Ethinyl estradiol and norgestimate Advanced Consumer Information (Micromedex®)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|
|AB||Products meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.|